Drug discovery informatics market size worth $5.62 billion by 2028 

The global drug discovery informatics market size is expected to reach $5.62 billion by 2028 according to a new study by Polaris Market Research. The report gives insight into current market dynamics and provides analysis on future market growth. 

The report is called “Drug Discovery Informatics Market Share, Size, Trends, Industry Analysis Report, By Workflow (Discovery Informatics, Development Informatics); By Mode (Outsourced, In-house); By Services (Sequence Analysis Platforms, Molecular Modeling, Docking, Clinical Trial Data Management, Others); By Regions; Segment Forecast, 2021 – 2028”. 

In 2020, the sequence analysis market segment accounted for the largest share and is likely to register a significant market growth over the study period. For sequence analysis, bioinformatics tools play an important role. They are widely used for the development of in-proprietary databases of protein, nucleic acid, and other biomolecule sequences. With the rising application of informatics solutions, gene sequencing is done through the identification of proteins and genes, which could further help in the development of potential drugs. 

Basic drug discovery requires the involvement of different sets of databases, sequence analysis tools, such as BLAST, FASTA, and CLUSTALW. Moreover, the introduction of new products and software tools with higher computing capabilities are further contributing to the segment’s market growth. In this line, in July 2019, Certara introduced its new version of D360, a drug discovery platform. The platform enabled analysis, representation and alignment of the small sections of peptides. 

The molecular modeling market segment is projected to witness a lucrative market growth over the study period. The technique is gaining popularity, owing to its wide applicability in the drug discovery process. Such tools are mostly used for the simulation of small molecules to predict their behavior at the molecular level. The technique is also able to accelerate cost-efficiency in the drug discovery process. 

Moreover, accelerated Covid-19 drug discovery programmes across the globe are further favouring the market growth. It helps in providing fast-track services, where scientists could perform virtual screening via drug from DrugBank, to target viral proteins and human ACE2 receptors. Such studies were also based on the in-silico tools to screen small molecules which have the potential to counter Covid-19. 

Similarly, companies in the marketplace are introducing services supporting or speeding up the drug development process. In this line, in June 2020, IBM visual molecular explorer platform was used to segregate a set of molecules targeting Covid-19. This is the open-source sharable AI-enabled platform involved in the initial screening of potential drug candidates. 

Read the full report on www.polarismarketresearch.com 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free